{"id":50171,"date":"2021-10-07T15:03:36","date_gmt":"2021-10-07T13:03:36","guid":{"rendered":"https:\/\/packaging-journal.de\/?p=50171"},"modified":"2024-05-12T15:53:47","modified_gmt":"2024-05-12T13:53:47","slug":"zero-emission-pharma","status":"publish","type":"post","link":"https:\/\/packaging-journal.de\/en\/null-emission-pharma\/","title":{"rendered":"Large companies want zero emissions in the pharmaceutical sector"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The aim is to achieve greater sustainability along the pharmaceutical supply chain. Eight renowned companies in the pharmaceutical supply chain have joined forces to achieve this. They have founded the non-profit \u201eAlliance to Zero\u201c to support pharmaceutical and biotech companies in their transition to net zero emissions in line with the Paris Climate Agreement. <\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The aim of the Alliance to Zero is to launch net-zero pharmaceutical products in regulated markets by 2030 at the latest. To achieve this, the founding members are committed to developing a joint net-zero product range by 2026. Pharmaceutical companies therefore have sufficient time to finalise their overall product on this basis.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Cooperation with non-profit organisations planned<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

To this end, the Alliance has developed a roadmap for a net-zero emissions concept in relation to pharmaceutical production and the supply chain. The necessary steps are currently being developed and a harmonised language and principles for assessing and controlling the overall emissions footprint of pharmaceutical end products are being defined. There are also plans to collaborate with academic and non-profit organisations pursuing similar goals.\u00a0<\/p>

\"\"<\/a><\/div><\/div>

One of the founding members of the alliance is Schreiner MediPharm as an expert in pharmaceutical speciality labels<\/strong>.<\/p>

\u201eFor us, co-founding the Alliance to Zero is another important step towards holistic sustainability. We are convinced that, together with the other alliance partners, we can drive forward the development of net zero pharmaceutical products\u201c
Dr Thomas Schweizer, Managing Director Schreiner MediPharm<\/strong><\/em><\/p><\/blockquote>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In addition to Schreiner MediPharm, the founding members include other well-known companies in the pharmaceutical and biotech value chain: D\u00e4twyler, Harro H\u00f6fliger, HealthBeacon, K\u00f6rber Pharma, SCHOTT, Sharp and Ypsomed. The alliance thus includes component suppliers, machine manufacturers and assembly\/manufacturing service providers, manufacturers of primary and secondary packaging as well as companies that are responsible for the final assembly of the products or handle their return after use.
\u00a0
For the founding members of the Alliance to Zero, collaboration along the pharmaceutical supply chain is an important step towards driving fundamental changes to improve the carbon footprint. Through close collaboration across traditional company boundaries and the special expertise and individual know-how of each cooperation partner, holistic solutions are being developed that will have a positive impact on the pharmaceutical industry.<\/p>